title: CARs in chronic lymphocytic leukemia -- ready to drive.
abstract: Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR(+) T cell therapy.
authors.affiliation: Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.affiliation: Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.affiliation: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: William
authors.initials: W
authors.lastname: Wierda
authors.affiliation: Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Bipulendu
authors.initials: B
authors.lastname: Jena
authors.affiliation: Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Laurence J N
authors.initials: LJN
authors.lastname: Cooper
authors.affiliation: Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Shpall
mesh_terms: D019264:Adoptive Transfer; D000951:Antigens, Neoplasm / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D050506:Mutant Chimeric Proteins / Q000276:immunology / Q000378:metabolism; D011946:Receptors, Antigen / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology* / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation
chemical_list: D000951:Antigens, Neoplasm; D050506:Mutant Chimeric Proteins; D011946:Receptors, Antigen; D011948:Receptors, Antigen, T-Cell